NAS:DTIL (USA)
Business Description
Precision BioSciences Inc
NAICS : 325412
SIC : 2834
302 East Pettigrew Street, Dibrell Building, Suite A-100, Durham, NC, USA, 27701
Compare
Compare
Traded in other countries / regions
PBS.Germany
•
DTIL.USA
Description
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The company's segments include Therapeutics and Food out of which the Therapeutics segment act as a key revenue driver for the firm.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.61 | |||||
| Equity-to-Asset | 0.35 | |||||
| Debt-to-Equity | 0.27 | |||||
| Debt-to-EBITDA | -0.34 | |||||
| Piotroski F-Score | 0/9 | |||||
| Altman Z-Score | -1.2 | |||||
| Beneish M-Score | 254.67 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 107 | |||||
| 3-Year EBITDA Growth Rate | 27.1 | |||||
| 3-Year EPS without NRI Growth Rate | 27.6 | |||||
| 3-Year FCF Growth Rate | 40.9 | |||||
| 3-Year Book Growth Rate | 22.5 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 79.64 | |||||
| 9-Day RSI | 71.18 | |||||
| 14-Day RSI | 65.01 | |||||
| 6-1 Month Momentum % | -67.32 | |||||
| 12-1 Month Momentum % | -87.15 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.59 | |||||
| Quick Ratio | 4.59 | |||||
| Cash Ratio | 3.41 | |||||
| Days Sales Outstanding | 102.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.5 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -264.55 | |||||
| Net Margin % | -247.31 | |||||
| ROE % | -99.57 | |||||
| ROA % | -40.43 | |||||
| ROIC % | -120.11 | |||||
| ROC (Joel Greenblatt) % | -270.37 | |||||
| ROCE % | -48.37 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 3.26 | |||||
| PB Ratio | 2.16 | |||||
| Price-to-Tangible-Book | 2.21 | |||||
| EV-to-EBIT | -0.72 | |||||
| EV-to-EBITDA | -0.8 | |||||
| EV-to-Forward-EBITDA | -0.69 | |||||
| EV-to-Revenue | 1.77 | |||||
| EV-to-Forward-Revenue | 3.36 | |||||
| EV-to-FCF | -0.63 | |||||
| Price-to-Net-Current-Asset-Value | 4.19 | |||||
| Earnings Yield (Greenblatt) % | -138.89 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Gurus Latest Trades with NAS:DTIL
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 37.512 | ||
| EPS (TTM) ($) | -1.49 | ||
| Beta | 1.85 | ||
| Volatility % | 58.22 | ||
| 14-Day RSI | 65.01 | ||
| 14-Day ATR ($) | 0.157294 | ||
| 20-Day SMA ($) | 1.6075 | ||
| 12-1 Month Momentum % | -87.15 | ||
| 52-Week Range ($) | 1.11 - 14.38 | ||
| Shares Outstanding (Mil) | 110.82 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 0 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Precision BioSciences Inc Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||